High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients (original) (raw)

FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease

Selim Kiliç

Kidney International, 2010

View PDFchevron_right

Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis

ORLANDO ORLANDO

New England Journal of Medicine, 2008

View PDFchevron_right

Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis

Hilmi Ataseven

Cumhuriyet medical journal, 2021

View PDFchevron_right

Change in FGF23 concentration over time and its association with all-cause mortality in patients treated with haemodialysis or haemodiafiltration

Menso Nubé

Ndt Plus, 2020

View PDFchevron_right

Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients

Kuniaki Otsuka

International Urology and Nephrology, 2014

View PDFchevron_right

FGF23 in patients with end-stage renal disease on hemodialysis

Yoshiki Nishizawa

Kidney International, 2004

View PDFchevron_right

Effect of Fibroblast Growth Factor-23 (FGF-23) on Two-Year Mortality Rate in Chronic Kidney Disease Patients With Hemodialysis

junita tarigan

Asian Journal of Medicine and Biomedicine, 2021

View PDFchevron_right

Fibroblast Growth Factor23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease

Orlando Gutierrez

2005

View PDFchevron_right

Serum fibroblast growth factor-23 levels in chronic haemodialysis patients

Salwa Ibrahim

International Urology and Nephrology, 2008

View PDFchevron_right

Outcomes of an Erythropoietic Growth Factor Interchange Program in Hospitalized Chronic Hemodialysis Patients

Bruce Mueller

Hospital Pharmacy, 2007

View PDFchevron_right

Model-Based Analysis of FGF23 Regulation in Chronic Kidney Disease

Joao Raposo

Gene Regulation and Systems Biology, 2010

View PDFchevron_right

FGF-23 and Phosphate in Children with Chronic Kidney Disease: A Cross-Sectional Study in Kazakhstan

Altynay Balmukhanova

Medicina-lithuania, 2020

View PDFchevron_right

Follistatin-Like-1 (FSTL1) Is a Fibroblast-Derived Growth Factor That Contributes to Progression of Chronic Kidney Disease

York Pei

International Journal of Molecular Sciences, 2021

View PDFchevron_right

Key Comorbid Conditions that Are Predictive of Survival among Hemodialysis Patients

Jennifer Bragg-Gresham

Clinical Journal of the American Society of Nephrology, 2009

View PDFchevron_right

The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort

Peter Kerr

BMC Nephrology, 2018

View PDFchevron_right

Assessment of Fibroblast Growth Factor-23 ( Fgf23) as Risk Factor for Diastolic Dysfunction in Hemodialysis Patients

Roxana Sadeghi

Journal of Nephrology & Renal Diseases

View PDFchevron_right

The dose of hemodialysis and patient mortality

Wendy Bloembergen

Kidney International, 1996

View PDFchevron_right

Fibroblast Growth Factor 23 in Patients Undergoing Peritoneal Dialysis

GABRIEL SEBASTIAN MENDOZA CONTRERAS

Clinical Journal of the American Society of Nephrology, 2011

View PDFchevron_right

FGF-23 removal is improved by on-line high-efficiency hemodiafiltration compared to conventional high flux hemodialysis

Bernard Canaud

Journal of Nephrology, 2013

View PDFchevron_right

Intensive Hemodialysis: Time to Give the Therapy Greater Consideration

Christopher Chan

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016

View PDFchevron_right

Prognostic Importance of Fibroblast Growth Factor-23 in Dialysis Patients

Selçuk Sezıklı, Ozlem Harmankaya

International Journal of Nephrology, 2014

View PDFchevron_right

Intact Fibroblast Growth Factor 23 and Peripheral Vascular Complications in Patients on Hemodialysis

Emre Asiltürk

Dicle Tıp Dergisi, 2020

View PDFchevron_right

Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship?

Bengt Lindholm

Nephrology Dialysis Transplantation, 2010

View PDFchevron_right

Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease

Janine Wirth

American Heart Journal, 2011

View PDFchevron_right

Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in coronary artery disease patients with diabetes mellitus

Jesus Egido

Diabetes/Metabolism Research and Reviews, 2016

View PDFchevron_right

Thrombosis in Hemodialysis Patients; Their Association with Tissue Factor and Tissue Factor Pathway Inhibitor

amal zaghloul

Internal Medicine: Open Access, 2015

View PDFchevron_right

Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients

Björn Meijers

Nephrology Dialysis Transplantation, 2011

View PDFchevron_right

Clinical signifi cance of FGF-23 measurement in dialysis patients

Maurizio Gallieni

Clinical Nephrology, 2011

View PDFchevron_right

Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients

Amein Al-Ali

Cardiorenal Medicine, 2015

View PDFchevron_right

Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals

Ambika Ashraf

Journal of Clinical & Translational Endocrinology, 2015

View PDFchevron_right

Study Of Fibroblast Growth Factor 23 (Fgf23) And Anemia In Hemodialysis Patients And Ckd Patients Stages 3 & 4

Magdy El-Sharkawy

Life Sciences

View PDFchevron_right

Dialysis. Pathophysiology and Clinical Studies

Giuseppe Palladino

Nephrology Dialysis Transplantation, 2014

View PDFchevron_right

High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients (original) (raw)

Related papers